Table 1.
Baseline characteristics according to LDLapoB/LDLCmeas quartiles in the entire LURIC cohort.
| 1st Quartile | 2nd Quartile | 3rd Quartile | 4th Quartile | p * | |
|---|---|---|---|---|---|
| Number | 836 | 810 | 821 | 824 | - |
| Male sex | 456 (54.5) | 570 (70.4) | 629 (76.6) | 639 (77.5) | <0.001 |
| Age, years | 63.3 (10.8) | 63.2 (10.6) | 62.6 (10.4) | 61.4 (10.6) | 0.001 |
| Body mass index, kg/m2 | 26.7 (3.9) | 27 (3.8) | 27.9 (4.2) | 28.4 (4.1) | <0.001 |
| Hypertension | 572 (68.4) | 588 (72.6) | 602 (73.3) | 629 (76.3) | 0.004 |
| Smoking | <0.001 | ||||
| Never | 396 (47.4) | 287 (35.4) | 269 (32.8) | 234 (28.4) | |
| Former | 302 (36.1) | 367 (45.3) | 372 (45.3) | 414 (50.2) | |
| Current | 138 (16.5) | 156 (19.3) | 180 (21.9) | 176 (21.4) | |
| Diabetes mellitus | 248 (29.7) | 284 (35.1) | 365 (44.5) | 414 (50.2) | <0.001 |
| Lipids | |||||
| Total cholesterol, mg/dL † | 207 (39) | 192 (34) | 187 (37) | 182 (42) | <0.001 |
| LDL cholesterol, mg/dL † | 135 (37) | 121 (29) | 114 (30) | 95.5 (29) | <0.001 |
| HDL cholesterol, mg/dL † | 45.5 (11.5) | 41 (10) | 36 (9) | 32 (8) | <0.001 |
| Triglycerides, mg/dL ‡ | 119 (45) | 140 (55) | 170 (64) | 264 (184) | <0.001 § |
| LDL triglycerides, mg/dL ‡ | 29 (10) | 30 (10) | 33 (12) | 34 (14) | <0.001 § |
| ApoB, mg/dL | 102 (25) | 103 (23) | 106 (25) | 107 (26) | <0.001 |
| LDL apo B, mg/dL | 87 (23) | 86 (20) | 86 (22) | 81(23) | <0.001 |
| LDL apolipoprotein B-to-LDL cholesterol ratio | 0.65 (0.03) | 0.71 (0.01) | 0.76 (0.02) | 0.86 (0.10) | - |
| LDL diameter, nm | 17.0 (0.4) | 16.6 (0.3) | 16.5 (0.3) | 16.2 (0.4) | <0.001 |
| C-reactive protein, mg/L | 6.1 (13.5) | 8.1 (15.3) | 10.8 (20.9) | 11.3 (21.1) | <0.001 § |
| Coronary artery disease || | <0.001 | ||||
| No | 289 (35) | 189 (23.4) | 127 (16.2) | 128 (16.2) | |
| Stable angina | 372 (45.1) | 388 (49.0) | 393 (50.1) | 378 (47.7) | |
| ACS | 164 (19.9) | 215 (27.1) | 265 (33.8) | 286 (36.1) | |
| NYHA functional class | 0.131 | ||||
| I | 432 (51.7) | 426 (52.6) | 437 (53.2) | 415 (50.4) | |
| II | 265 (31.7) | 233 (28.8) | 229 (27.9) | 235 (28.5) | |
| III | 126 (15.1) | 125 (15.4) | 124 (15.1) | 146 (17.7) | |
| IV | 13 (1.6) | 26 (3.2) | 31 (3.8) | 28 (3.4) | |
| Left ventricular function # | <0.001 | ||||
| Normal | 566 (70.8) | 502 (64.2) | 447 (56.4) | 454 (57.2) | |
| Mildly impaired | 99 (12.4) | 113 (14.5) | 126 (15.9) | 122 (15.4) | |
| Moderately impaired | 62 (7.8) | 83 (10.6) | 103 (13) | 102 (12.8) | |
| Severely impaired | 23 (2.9) | 36 (4.6) | 44 (5.5) | 41 (5.2) | |
| Friesinger score | <0.001 | ||||
| 1st quartile | 282 (33.7) | 176 (21.7) | 121 (14.7) | 135 (16.4) | |
| 2nd quartile | 223 (26.7) | 182 (22.5) | 168 (20.5) | 168 (20.4) | |
| 3rd quartile | 202 (24.2) | 261 (32.2) | 304 (37) | 295 (35.8) | |
| 4th quartile | 129 (15.4) | 191 (23.6) | 228 (27.8) | 226 (27.4) | |
| Peripheral vascular disease | 49 (5.9) | 77 (9.5) | 82 (10) | 101 (12.3) | <0.001 |
| Cerebrovascular disease | 74 (8.9) | 62 (7.7) | 86 (10.5) | 77 (9.3) | 0.256 |
| Lipid-lowering drugs | |||||
| Statin | 231 (27.6) | 337 (41.6) | 472 (57.5) | 503 (61) | <0.001 |
| Non-statin lipid-lowering drugs | 17 (2) | 21 (2.6) | 15 (1.8) | 26 (3.2) | 0.288 |
Legend: Values are means ± standard deviations or medians (25th–75th percentiles) in cases of continuous variables and numbers (percentages) in cases of categorical data. * For differences across the four groups calculated with the χ2 test and Analysis of Variance for categorical and continuous data, respectively. † To convert to millimoles per liter, multiply by 0.02586. ‡ To convert to millimoles per liter, multiply by 0.01129. § Analysis Of Variance of logarithmically transformed values. || 825/792/785/792. # 750/734/720/719.